ライフサイエンスコーパス: metronidazole

1 ampicillin, sulfamethoxazole, gentamicin, or metronidazole).

2 d intra-abdominal infections (when used with metronidazole).

3 played by the combination of amoxicillin and metronidazole.

4 hoc combination of data for amoxicillin and metronidazole.

5 , toxin-binding polymer, with vancomycin and metronidazole.

6 and a 7-day prescription of amoxicillin and metronidazole.

7 or same-day FDIS, with or without adjunctive metronidazole.

8 e charge in mice faeces 1-2-fold faster than metronidazole.

9 ated with the combination of paromomycin and metronidazole.

10 ad no specific benefit from amoxicillin plus metronidazole.

11 e of intravenous beta-lactam antibiotic plus metronidazole.

12 imes more potent against E. histolytica than metronidazole.

13 polymicrobial antibiotic coverage, including metronidazole.

14 ere CDI, for which it is more effective than metronidazole.

15 ata to support the use of sulphasalazine and metronidazole.

16 reaction and were treated with 2.0 g of oral metronidazole.

17 data to support the use of sulfasalazine and metronidazole.

18 mized to receive intravaginal clindamycin or metronidazole.

19 om patients undergoing treatment for BV with metronidazole.

20 ound to have H. pylori isolates resistant to metronidazole.

21 nd is resistant to isoniazid, rifampicin and metronidazole.

22 biotics, but ceased following treatment with metronidazole.

23 doxin oxidoreductase and may be sensitive to metronidazole.

24 Diffusion of water, metronidazole (0.5%), dexamethasone (0.2%), ciprofloxaci

25 ot differ significantly (P = .8) between the metronidazole (-1.8 CI, [-2.5, -1.1]) and the placebo gr

26 lindamycin (100% resistant to 2 mug/mL), and metronidazole (100% resistant to 4 mug/mL).

27 tro subgingival biofilm model was exposed to metronidazole (15 mug/mL), amoxicillin (15 mug/mL), metr

28 ) for clarithromycin, 44% (95% CI 39-48) for metronidazole, 18% (95% CI 15-22) for levofloxacin, 3% (

29 Treatment relies on metronidazole(2), which has adverse effects(3), and pote

30 d to one of four treatment groups: 1) FDIS + metronidazole; 2) FDIS + placebo; 3) SRP + metronidazole

31 ted to one of four treatment groups: 1) FDIS+metronidazole; 2) FDIS+placebo; 3) SRP+metronidazole; or

32 comycin 125 mg every 6 hours for 10 days, or metronidazole 375 mg every 6 hours for 10 days.

33 acebo; (2) amoxicillin (500 mg twice daily), metronidazole (400 mg twice daily), and omeprazole (20 m

34 y); or (3) azithromycin (500 mg once daily), metronidazole (400 mg twice daily), and omeprazole (20 m

35 months and randomized to treatment with oral metronidazole 500 mg twice daily for 7 days or observati

36 of oral levofloxacin (500 mg once daily) and metronidazole (500 mg 3 times per day).

37 d either ceftolozane/tazobactam (1.5 g) plus metronidazole (500 mg) every 8 hours or meropenem (1 g)

38 gned to receive oral cephalexin, 500 mg, and metronidazole, 500 mg (n = 202 participants), vs identic

39 Evidence supports metronidazole, 500 mg every 6 hours for 10 to 14 days, a

40 strains); (iv) heightened susceptibility to metronidazole (6 of 17 strains); and (v) decreased motil

41 All 450 participants received oral metronidazole (7 days) and were equally randomized to va

42 to receive vaginal suppositories containing metronidazole 750 mg plus miconazole 200 mg or matching

43 cent vaginal infection received intravaginal metronidazole 750 mg plus miconazole 200 mg or placebo f

44 nited States and Kenya received intravaginal metronidazole (750 mg) plus miconazole (200 mg) or place

45 Metronidazole, a 5-nitroimidazole, is often used as empi

46 stigated include: tetracycline, minocycline, metronidazole, a group of other antibiotics, chlorhexidi

47 ions in several genes, most likely affecting metronidazole activation, and produced no false positive

48 either necessary for hydrogen production nor metronidazole activation.

49 m that does not require either PFO or Fd for metronidazole activation.

50 oncomitant administration of amoxicillin and metronidazole adjunctive to SRP in adults who are otherw

51 erococcal domination was increased 3-fold by metronidazole administration, whereas domination by Prot

52 and amoxicillin alone or in combination with metronidazole, albeit by less than 1 log.

53 Metronidazole alone did not affect biofilm composition.

54 ibiotics was found to be more efficient than metronidazole alone; however, only minor differences in

55 0-to-14-day course of empirical therapy with metronidazole, alone or in combination with a fluoroquin

56 vere periodontitis (n = 24), amoxicillin and metronidazole (AM) were prescribed for 7 days.

57 vere periodontitis (N = 24), amoxicillin and metronidazole (AM) were prescribed for 7 days.

58 gic, and immunologic benefits of amoxicillin/metronidazole (AM) when performing full-mouth ultrasonic

59 They are generally resistant to metronidazole, aminoglycosides and ciprofloxacin with L.

60 The systemic use of combined amoxicillin and metronidazole (AMX/MET) as an adjunctive treatment to fu

61 The combination of Amoxicillin and metronidazole (AMX/MET) as an adjunctive treatment to sc

62 nt fractions and potentiates the activity of metronidazole, an antimicrobial agent used in the treatm

63 dazole (15 mug/mL), amoxicillin (15 mug/mL), metronidazole and amoxicillin in combination, doxycyclin

64 with a single high dose of streptozotocin or metronidazole and anesthetized at 3, 7, or 14 days or pa

65 Metronidazole and carbapenems exhibited reliable activit

66 Like its progenitors metronidazole and CGI-17341, PA-824 is a prodrug of the

67 Metronidazole and ciprofloxacin selectively treat coloni

68 Metronidazole and clarithromycin are the two key antibio

69 und Methanobrevibacter oralis susceptible to metronidazole and fusidic acid.

70 % (23/26) in the ceftolozane/tazobactam plus metronidazole and meropenem groups, respectively, and 10

71 esses, in whom antibiotic therapy comprising metronidazole and meropenem was partly beneficial in imp

72 l cure rates with ceftazidime-avibactam plus metronidazole and meropenem, respectively, were as follo

73 s treated with ronidazole, dimetridazole and metronidazole and non-medicated animals (controls), at t

74 Metronidazole and other 5-nitroimidazoles (5-NI) are amo

75 occus; the isolate was catalase positive and metronidazole and penicillin resistant.

76 Of 96 participants, 48 were allocated to the metronidazole and placebo group each.

77 al success of tolevamer was inferior to both metronidazole and vancomycin (P < .001), and metronidazo

78 The relative impacts of metronidazole and vancomycin on the intestinal microbiot

79 ome at any point, and decreased equally with metronidazole and vancomycin.

80 s L. rhamnosus and L. casei are resistant to metronidazole and vancomycin.

81 widespread clinical experience suggest that metronidazole and/or ciprofloxacin can treat Crohn's col

82 estigated the effect of brief treatment with metronidazole and/or oral vancomycin on susceptibility t

83 specimens collected prior to treatment with metronidazole and/or vancomycin, a significant correlati

84 The initial treatment in 82% of patients was metronidazole, and 18% experienced treatment failure.

85 63 patients received tolevamer, 289 received metronidazole, and 266 received vancomycin.

86 20 study subjects, 101 (84%) were started on metronidazole, and 33 of those (33%) were subsequently g

87 were cefoxitin sodium, cefazolin sodium with metronidazole, and ampicillin sodium-sulbactam sodium, r

88 ults occurred for tetracycline, minocycline, metronidazole, and chlorhexidine.

89 pylori eradication therapy using omeprazole, metronidazole, and clarithromycin was administered p.o.

90 uding cefazolin/metronidazole, ciprofloxacin/metronidazole, and ertapenem.

91 t antibiotics used to treat CDI (vancomycin, metronidazole, and fidaxomicin) is a desired trait in su

92 th clavulanate, ampicillin, chloramphenicol, metronidazole, and penicillin were determined using a gr

93 In contrast, vancomycin, metronidazole, and rifaximin (at similar sub-MICs) did n

94 netics was compared with that of vancomycin, metronidazole, and rifaximin.

95 ding a single capsule that contains bismuth, metronidazole, and tetracycline.

96 th amoxicillin/clavulanic acid, clindamycin, metronidazole, and the combination therapy metronidazole

97 ntibiotics (kanamycin, gentamicin, colistin, metronidazole, and vancomycin) for 3 days.

98 polymyxin B, and Abx (ampicillin, neomycin, metronidazole, and vancomycin).

99 virulence and incidence, more resistance to metronidazole, and worse outcomes.

100 + metronidazole; 2) FDIS + placebo; 3) SRP + metronidazole; and 4) SRP + placebo.

101 enzymatic prodrug therapy with conventional metronidazole antibiotics.

102 erculosis (Mtb) while 5-nitroimidazoles like metronidazole are active against only anaerobic Mtb.

103 Vancomycin and metronidazole are first-line therapies for most patients

104 rate that vancomycin, and to a lesser extent metronidazole, are associated with marked intestinal mic

105 cited at 365nm which quenched in presence of Metronidazole as a template molecule..

106 erapy using a combination of amoxicillin and metronidazole as an adjunct to SRP can enhance the clini

107 Hinton agar and to the inhibitory effects of metronidazole at 16 mg/L in an enriched Brucella blood a

108 amycin at 4 mg/L, doxycycline at 4 mg/L, and metronidazole at 16 mg/L, with a post hoc combination of

109 to ciprofloxacin, and 90% were resistant to metronidazole at 16 mg/L.

110 ionally evaluated for in vitro resistance to metronidazole at 4 mug/mL.

111 ApoE(+/-) mice that received either DPG3 or metronidazole before P. gingivalis than from ApoE(+/-) m

112 CFU); a fimbria-deficient P. gingivalis; or metronidazole before P. gingivalis.

113 (SRP) plus placebo capsule; and 3) SRP plus metronidazole capsule (250 mg t.i.d. for one week).

114 ere treated with broad-spectrum antibiotics (metronidazole, ciprofloxacin) after transplantation.

115 ed with lower SSI rates, including cefazolin/metronidazole, ciprofloxacin/metronidazole, and ertapene

116 Virgin transgenic mice were treated with metronidazole/ciprofloxacin or gentamicin through the dr

117 val (95% CI)] of breast cancer occurrence in metronidazole/ciprofloxacin-treated mice was more than t

118 (proton pump inhibitor [PPI] + amoxicillin + metronidazole + clarithromycin [PAMC]) and traditional b

119 ceptibility testing of H. pylori isolates to metronidazole, clarithromycin, amoxicillin, and tetracyc

120 Resistance to metronidazole, clarithromycin, and levofloxacin is more

121 The prevalence of metronidazole, clarithromycin, and levofloxacin resistan

122 py) vs oral vancomycin with intravenous (IV) metronidazole (combination therapy).

123 For now, vancomycin or metronidazole combined with discontinuation of antibioti

124 While first-line antibiotic treatment (metronidazole) commonly kills the protozoan pathogen, it

125 r samples treated with either amoxicillin or metronidazole compared with controls (P <0.05).

126 rative 48-hour course of oral cephalexin and metronidazole, compared with placebo, reduced the rate o

127 nsoprazole, amoxicillin, clarithromycin, and metronidazole (concomitant therapy); or 5 days of lansop

128 nsoprazole, amoxicillin, clarithromycin, and metronidazole (concomitant).

129 nd used as a selective fluorescent probe for Metronidazole detection.

130 The limit of detection for metronidazole determination was obtained 0.15muM.

131 tment of asymptomatic BV with 1 week of oral metronidazole did not decrease the incidence of gonorrhe

132 Amoxicillin plus metronidazole did not significantly affect the resistanc

133 dontal therapy supplemented with amoxicillin-metronidazole during either the non-surgical or the surg

134 d OP-1118 (unlike vancomycin, rifaximin, and metronidazole) effectively inhibited sporulation by C. d

135 by combination rifampicin, moxifloxacin, and metronidazole for 6 months is effective.

136 ived FMUD and 375 mg amoxicillin plus 250 mg metronidazole for 7 days.

137 al cure rate with ceftazidime-avibactam plus metronidazole for ceftazidime-resistant infections was c

138 Current recommendations include metronidazole for treatment of mild to moderate CDI and

139 ice with oral antibiotics (ciprofloxacin and metronidazole) for 3 weeks, which reduced bacterial load

140 vancomycin treatment is more effective than metronidazole; for mild disease either agent can be used

141 Both vancomycin and metronidazole further suppressed microbiome components d

142 rial vaginosis was treated with intravaginal metronidazole gel (0.75%), 37.5 mg nightly for 5 nights.

143 month after a 5-day course of vaginal 0.75% metronidazole gel and analyzed for 24 subjects with cure

144 s benefit specifically from amoxicillin plus metronidazole given as an adjunct to full-mouth scaling

145 axis group, compared to 3.3% in the SRP plus metronidazole group and 0.8% in the SRP plus placebo gro

146 agnosed in 13 women (6.4%) in the cephalexin-metronidazole group vs 31 women (15.4%) in the placebo g

147 D. fragilis was significantly greater in the metronidazole group, although it declined rapidly from 6

148 Metronidazole had a significant, adjunctive effect in pa

149 Metronidazole had no association with future CDAD.

150 The anaerobic drug metronidazole has antituberculous activity under hypoxic

151 o corticosteroids, infliximab or adalimumab, metronidazole, hospitalizations, higher ambulatory care

152 It may be concluded that amoxicillin/metronidazole improves clinical and microbiologic result

153 ing was proportional to the concentration of Metronidazole in a linear range of at least 0.2muM to 15

154 A novel optical nanosensor for detection of Metronidazole in biological samples was reported.

155 have suggested an increased failure rate of metronidazole in Clostridium difficile associated diseas

156 alf-life, over 2-5 min (combined with 500 mg metronidazole in colorectal surgery).

157 bination therapy with oral vancomycin and IV metronidazole in critically ill patients with CDI.

158 the clinical and microbiological efficacy of metronidazole in Danish children.

159 ull-dose proton-pump inhibitor and high-dose Metronidazole in group A, and full-dose proton-pump inhi

160 al treatment associated with amoxicillin and metronidazole in individuals with aggressive periodontit

161 treatment failures have been associated with metronidazole in severe or complicated cases of CDI.

162 gested that prescription of amoxicillin plus metronidazole in the context of periodontal therapy shou

163 Although use of metronidazole in the treatment of polymicrobial infectio

164 umvent the resistance mechanism that renders metronidazole ineffectiveness in drug resistance cases o

165 Metronidazole inhibits the ferredoxin/hydrogenase pathwa

166 Metronidazole is appropriate for mild disease.

167 Previous use of macrolides and metronidazole is associated with H. pylori resistant to

168 ization of naturally abundant (15)N sites in metronidazole is demonstrated using SABRE-SHEATH (Signal

169 tron transfer rate between Tvfd and the drug metronidazole is due to the increased access of the anti

170 Treatment with oral metronidazole is effective, and T. vaginalis DNA disappe

171 se proton-pump inhibitor and higher doses of Metronidazole is essential to achieve such results.

172 he number of patients that do not respond to metronidazole is increasing.

173 Metronidazole is often used for treatment, though eradic

174 Reliance upon metronidazole is questioned due to a lower response rate

175 Metronidazole is the drug of choice.

176 d, which may be of substantial importance as metronidazole is widely used in human medicine.

177 PPI + clarithromycin + either amoxicillin or metronidazole) is restricted to areas with known low cla

178 y, 26%; Spain, 19.5%), 33% were resistant to metronidazole (Italy, 33%; Spain, 34%), and 8.8% were re

179 t associated with the use of amoxicillin and metronidazole led to an improvement in all clinical para

180 The application of metronidazole led to retractions of major processes asso

181 ower than the five antibiotics, amoxicillin, metronidazole, levofloxacin, tetracyclin, and clarithrom

182 n delivery, prophylactic oral cephalexin and metronidazole may be warranted.

183 Sulfasalazine and metronidazole may prove to be useful, therapeutic option

184 infection (FDIS), with or without adjunctive metronidazole (MET).

185 crobiologic effects of the adjunctive use of metronidazole (MTZ) and amoxicillin (AMX) in the treatme

186 NTR converts the antibiotic metronidazole (Mtz) into an interstrand DNA cross-linker

187 Metronidazole (MTZ) is often used in combination therapi

188 This enzyme converts the innocuous prodrug metronidazole (MTZ) to a cytotoxin.

189 ams) or 7-day (500 mg twice daily) multidose metronidazole (MTZ) treatment.

190 s found to be responsible for sensitivity to metronidazole (Mtz), a common therapeutic agent for anot

191 Metronidazole (MTZ), which has activity only against ana

192 uggested, however, upon finding two types of metronidazole (Mtz)-susceptible strains: type I, in whic

193 nly treated with the 5-nitroimidazole (5-NI) metronidazole (Mz), and yet treatment failures and Mz re

194 Treatment with metronidazole, nitazoxanide, and albendazole failed to e

195 nd systemically administered amoxicillin and metronidazole or as GR (n = 30) based on mean attachment

196 g/mL), including strains resistant to either metronidazole or clarithromycin or both.

197 Polymersome-encapsulated metronidazole or doxycycline significantly (P<0.05) redu

198 Polymersome-encapsulated metronidazole or doxycycline, free metronidazole, or dox

199 Metronidazole or oral vancomycin can cure C. difficile i

200 on in a 1:1 ratio to a 10-day course of oral metronidazole or placebo.

201 ontrol and root planing plus amoxicillin and metronidazole or to a control treatment group (CTG) (n =

202 of patients with C difficile infection with metronidazole or vancomycin reduces morbidity and mortal

203 CDI occurs in more than 20% of patients when metronidazole or vancomycin treatment is discontinued.

204 Patients with symptomatic CDI taking metronidazole or vancomycin were enrolled.

205 ed metronidazole with vancomycin; 8 compared metronidazole or vancomycin with another agent, combined

206 linically recovered following treatment with metronidazole or vancomycin, oral administration of spor

207 ifficile infection who were receiving either metronidazole or vancomycin.

208 istant in vitro to doxycycline, amoxicillin, metronidazole, or clindamycin, in 55%, 43.3%, 30.3%, and

209 apsulated metronidazole or doxycycline, free metronidazole, or doxycycline, or polymersomes alone as

210 th increasing concentrations of amoxicillin, metronidazole, or their combination and incubated anaero

211 FDIS+metronidazole; 2) FDIS+placebo; 3) SRP+metronidazole; or 4) SRP+placebo.

212 er-quality evidence is available for topical metronidazole, oral tetracycline, laser and light-based

213 nd had successfully completed treatment with metronidazole, oral vancomycin, or both at 44 study cent

214 nidazole was associated with previous use of metronidazole (P < 0.001).

215 ore likely than male patients to demonstrate metronidazole (P < 0.05) and clarithromycin (P < 0.05) r

216 enems (p=0.0013), vancomycin (p=0.0040), and metronidazole (p=0.0004) following the intervention.

217 ammatory cytokines in both DPG3-injected and metronidazole/P. gingivalis-treated ApoE(+/-) mice compa

218 success, the two groups receiving adjunctive metronidazole performed significantly better than the tw

219 nce of potentially interfering drugs such as metronidazole, phenobarbital, chlorpheniramine maleate,

220 plus 150 mg of fluconazole was compared with metronidazole placebo plus fluconazole placebo.

221 A trial intervention of 2 g of metronidazole plus 150 mg of fluconazole was compared wi

222 eatment groups: group A, antibiotics (500 mg metronidazole plus 375 mg amoxicillin three times per da

223 , metronidazole, and the combination therapy metronidazole plus amoxicillin.

224 Monthly treatment with intravaginal metronidazole plus miconazole reduced the proportion of

225 H2 receptor blockers, plus clarithromycin or metronidazole, plus amoxicillin or tetracycline, with or

226 a colon cancer xenograft with the antibiotic metronidazole reduced Fusobacterium load, cancer cell pr

227 biological molecule that activates the drug metronidazole reductively in the treatment of trichomoni

228 sults and technical ease of performance; and metronidazole replaced vancomycin as standard treatment,

229 ns in bacterial genomes and used it to study metronidazole resistance in H. pylori.

230 Metronidazole resistance was demonstrated in isolates fr

231 l clarithromycin resistance, while levels of metronidazole resistance were similar in all multilocus

232 fections in areas of high clarithromycin and metronidazole resistance.

233 l), 10/247 isolates tested were resistant to metronidazole (resistance breakpoint >/= 32 mug/ml), and

234 udies suggest that the association between a metronidazole-resistant anaerobe, Atopobium vaginae, and

235 cians need to be aware of the possibility of metronidazole-resistant B. fragilis strains in the Unite

236 We report a case of metronidazole-resistant Bacteroides fragilis in the Unit

237 s against both metronidazole-susceptible and metronidazole-resistant G. lamblia isolates, and their e

238 The Giardia viability studies in the metronidazole-resistant strain and the G. lamblia CK irr

239 Ferredoxin, Fd, is often deficient in metronidazole-resistant strains of Trichomonas vaginalis

240 Although metronidazole resulted in transient loss of colonization

241 Treating transgenic adults with metronidazole resulted in two rod cell death models.

242 Tetracycline, erythromycin, clindamycin, and metronidazole revealed poor in vitro activity against hu

243 ficant, adjunctive effect in patients with a metronidazole-sensitive subgingival microbiota on the cl

244 5 days of lansoprazole, clarithromycin, and metronidazole (sequential therapy).

245 d by 5-day lansoprazole, clarithromycin, and metronidazole (sequential); or 5-day lansoprazole, amoxi

246 at empirical therapy with either imipenem or metronidazole should be considered.

247 bacilli after the establishment of hypoxia, metronidazole showed no antituberculous activity in this

248 ApoE(+/-) mice injected with DPG3 or metronidazole showed significantly fewer atheromatous le

249 To directly test whether Fd is essential for metronidazole susceptibility, gene replacement technolog

250 All strains were ciprofloxacin resistant and metronidazole susceptible, and 8.3% and 13.0% of the iso

251 nalog, thiram, their activities against both metronidazole-susceptible and metronidazole-resistant G.

252 l bismuth quadruple therapy (PPI + bismuth + metronidazole + tetracycline [PBMT]).

253 Adjunctive metronidazole therapy did not improve pregnancy outcome.

254 n vaginal bacterial concentrations following metronidazole therapy for BV.

255 accessible anastomosis, received 3 months of metronidazole therapy.

256 ients received 375 mg amoxicillin and 500 mg metronidazole three times per day for 7 days during the

257 lemented with 375 mg amoxicillin plus 500 mg metronidazole, three times daily for 7 days.

258 c antibiotics (375 mg amoxicillin and 500 mg metronidazole, three times daily) or placebo for 7 days.

259 ton-Pump Inhibitor + Clarithromycin 500 mg + Metronidazole/Tinidazole 500 mg bid/tid in the following

260 g a bacterial nitroreductase, which converts metronidazole to a cytotoxin, specifically in podocytes

261 noninferiority of ceftazidime-avibactam plus metronidazole to meropenem in the microbiologically modi

262 patocytes were depleted by administration of metronidazole to Tg(fabp10a:CFP-NTR) animals.

263 Application of the prodrug metronidazole to the transgenic fish induces acute damag

264 In metronidazole-treated myl7:nitroreductase embryos, myoca

265 Metronidazole treatment amplified these proinflammatory

266 Chronic metronidazole treatment decreases colonic mucosal hsp25

267 ence, BI/NAP1, and recognition of increasing metronidazole treatment failures as well as the morbidit

268 surements of 11 key bacterial species during metronidazole treatment for 15 cases of BV.

269 s do not provide evidence to support routine metronidazole treatment of D. fragilis positive children

270 rella vaginalis and Mycoplasma hominis, only metronidazole treatment resulted in a significant decrea

271 y bacterial vaginosis flora before and after metronidazole treatment.

272 rprisingly, Fd KO cells are not resistant to metronidazole under aerobic or anaerobic conditions.

273 Amoxicillin/metronidazole used as an adjunct to the FMUD protocol ad

274 o hyperpolarized more distant (15)N sites in metronidazole using longer-range spin-spin couplings (J(

275 Oral antibiotics such as metronidazole, vancomycin and fidaxomicin are therapies

276 a population with a median age of 65 years: metronidazole, vancomycin, fidaxomicin, and fecal microb

277 onstrate clinical success rates of 66.3% for metronidazole vs 78.5% for vancomycin for severe CDI.

278 who receive prophylactic oral cephalexin and metronidazole vs placebo for 48 hours following cesarean

279 clinical trial comparing oral cephalexin and metronidazole vs placebo for 48 hours following cesarean

280 ess in patients with severe CDI who received metronidazole was 66.3% compared with vancomycin, which

281 imit of detection (2.0 log10 CFU/g), whereas metronidazole was associated with mean C. difficile coun

282 de antibiotic (P < 0.001), and resistance to metronidazole was associated with previous use of metron

283 safety profile of ceftazidime-avibactam plus metronidazole was consistent with that previously observ

284 metronidazole and vancomycin (P < .001), and metronidazole was inferior to vancomycin (P = .02; 44.2%

285 inferior to antibiotic treatment of CDI, and metronidazole was inferior to vancomycin.

286 Ceftazidime-avibactam plus metronidazole was noninferior to meropenem across all pr

287 Treatment with ceftolozane/tazobactam plus metronidazole was noninferior to meropenem in adult pati

288 Ceftolozane/tazobactam plus metronidazole was noninferior to meropenem in the primar

289 Ceftazidime-avibactam plus metronidazole was noninferior to meropenem in the treatm

290 Fidaxomicin and metronidazole were both dominated by FMT colonoscopy.

291 acy and safety of ceftazidime-avibactam plus metronidazole were compared with meropenem in 1066 men a

292 ot planing (SRP), with or without adjunctive metronidazole, when treating chronic destructive periodo

293 ceptibility, only 3 (0.3%) were resistant to metronidazole, whereas clindamycin resistance increased

294 Finally, metronidazole, which has potent bactericidal activity in

295 c rifampicin, as well as with the antibiotic metronidazole, which targets hypoxic bacterial populatio

296 pathogens resistant to both amoxicillin and metronidazole, which were mostly either S. constellatus

297 ubgroup analysis of a single study comparing metronidazole with vancomycin for patients who have seve

298 Three trials compared metronidazole with vancomycin; 8 compared metronidazole

299 in the combination therapy group received IV metronidazole within 48 hours after initiating vancomyci

300 estigate this, we applied the nitroreductase/metronidazole zebrafish model of podocyte injury to in v